Advertisement

Heart Failure pp 121-127 | Cite as

Pharmacotherapy in Heart Failure (II): Beta Adrenergic Blocking Drugs, Ivabradine, Hydralazine and Nitrates

  • Shirin ZarafsharEmail author
  • Michael B Fowler
Chapter
Part of the Cardiovascular Medicine book series (CVM)

Abstract

Sympathetic nervous system activation is a cardinal feature of heart failure. Cannon [1] first described this component of the autonomic nervous system as the “fight or flight response” which became activated to react to short bursts of activity associated with “pain, hunger, fear or rage.” The principal responses seen in the cardiovascular system are an increase in heart rate and myocardial contractility, an increase in peripheral vasoconstriction, and other alterations in vascular tone causing redirection of blood flow to vital organs. Chidsey [2] was one of the earliest investigators to demonstrate that heart failure was accompanied by chronic activation of the sympathetic nervous system. This was at one time felt to be a beneficial response, helping to restore cardiac output through inotropic and chronotropic actions which were held to be beneficial to the failing heart. Beta adrenergic blocking drugs were believed to be contraindicated in heart failure and labeled as such. An improved understanding of the potential detrimental effects of chronic sympathetic activation emerged with new insights into the pathophysiology of heart failure, and from small clinical studies which suggested patients with heart failure could benefit from treatment with beta adrenergic blockade.

References

  1. 1.
    Cannon W. Bodily changes in pain, hunger, fear, and rage. Philadelphia: Saunders; 1929.CrossRefGoogle Scholar
  2. 2.
    Chidsey CA, Braunwald E, Morrow AG. Catecholamine excretion and cardiac stores of norepinephrine in congestive heart failure. Am J Med. 1965;39:442–51.CrossRefGoogle Scholar
  3. 3.
    Cohn JN, Levine TB, Olivari MT, Garberg V, Lura D, Francis GS, et al. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med. 1984;311(13):819–23.CrossRefGoogle Scholar
  4. 4.
    Bristow MR, Ginsburg R, Minobe W, Cubicciotti RS, Sageman WS, Lurie K, et al. Decreased catecholamine sensitivity and beta-adrenergic-receptor density in failing human hearts. N Engl J Med. 1982;307(4):205–11.CrossRefGoogle Scholar
  5. 5.
    Cohn JN, Levine TB, Francis GS, Goldsmith S. Neurohumoral control mechanisms in congestive heart failure. Am Heart J. 1981;102(3 Pt 2):509–14.CrossRefGoogle Scholar
  6. 6.
    Waagstein F, Hjalmarson A, Varnauskas E, Wallentin I. Effect of chronic beta-adrenergic receptor blockade in congestive cardiomyopathy. Br Heart J. 1975;37(10):1022–36.CrossRefGoogle Scholar
  7. 7.
    Heilbrunn SM, Shah P, Bristow MR, Valantine HA, Ginsburg R, Fowler MB. Increased beta-receptor density and improved hemodynamic response to catecholamine stimulation during long-term metoprolol therapy in heart failure from dilated cardiomyopathy. Circulation. 1989;79(3):483–90.CrossRefGoogle Scholar
  8. 8.
    Engelmeier RS, O'Connell JB, Walsh R, Rad N, Scanlon PJ, Gunnar RM. Improvement in symptoms and exercise tolerance by metoprolol in patients with dilated cardiomyopathy: a double-blind, randomized, placebo-controlled trial. Circulation. 1985;72(3):536–46.CrossRefGoogle Scholar
  9. 9.
    Waagstein F, Bristow MR, Swedberg K, Camerini F, Fowler MB, Silver MA, et al. Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy. Metoprolol in Dilated Cardiomyopathy (MDC) Trial Study Group. Lancet. 1993;342(8885):1441–6.CrossRefGoogle Scholar
  10. 10.
    Bristow MR, O’Connell JB, Gilbert EM, French WJ, Leatherman G, Kantrowitz NE, et al. Dose-response of chronic beta-blocker treatment in heart failure from either idiopathic dilated or ischemic cardiomyopathy. Bucindolol Investigators. Circulation. 1994;89(4):1632–42.CrossRefGoogle Scholar
  11. 11.
    Packer M, Bristow MR, Cohn JN, Colucci WS, Fowler MB, Gilbert EM, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group.[see comment]. N Engl J Med. 1996;334(21):1349–55.CrossRefGoogle Scholar
  12. 12.
    MERIT-HF group. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet. 1999;353(9169):2001–2007.Google Scholar
  13. 13.
    CIBIS-II Investigators and Committees. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet. 1999;353(9146):9–13.Google Scholar
  14. 14.
    Packer M, Coats AJ, Fowler MB, Katus HA, Krum H, Mohacsi P, et al. Effect of carvedilol on survival in severe chronic heart failure.[see comment]. N Engl J Med. 2001;344(22):1651–8.CrossRefGoogle Scholar
  15. 15.
    Bakris GL, Fonseca V, Katholi RE, McGill JB, Messerli FH, Phillips RA, et al. Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial. JAMA. 2004;292(18):2227–36.CrossRefGoogle Scholar
  16. 16.
    Poole-Wilson PA, Swedberg K, Cleland JG, Di Lenarda A, Hanrath P, Komajda M, et al. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. Lancet. 2003;362(9377):7–13.CrossRefGoogle Scholar
  17. 17.
    Fonarow GC, Abraham WT, Albert NM, Gattis WA, Gheorghiade M, Greenberg B, et al. Organized program to initiate lifesaving treatment in hospitalized patients with heart failure (OPTIMIZE-HF): rationale and design. Am Heart J. 2004;148(1):43–51.CrossRefGoogle Scholar
  18. 18.
    Gilbert EM, Hershberger RE, Wiechmann RJ, Movsesian MA, Bristow MR. Pharmacologic and hemodynamic effects of combined beta-agonist stimulation and phosphodiesterase inhibition in the failing human heart. Chest. 1995;108(6):1524–32.CrossRefGoogle Scholar
  19. 19.
    Beta-Blocker Evaluation of Survival Trial I. A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure. N Engl J Med. 2001;344(22):1659–67.CrossRefGoogle Scholar
  20. 20.
    Port JD, Bristow MR. Altered beta-adrenergic receptor gene regulation and signaling in chronic heart failure. J Mol Cell Cardiol. 2001;33(5):887–905.CrossRefGoogle Scholar
  21. 21.
    Cohn JN, Pfeffer MA, Rouleau J, Sharpe N, Swedberg K, Straub M, et al. Adverse mortality effect of central sympathetic inhibition with sustained-release moxonidine in patients with heart failure (MOXCON). Eur J Heart Fail. 2003;5(5):659–67.CrossRefGoogle Scholar
  22. 22.
    Ghali JK, Pina IL, Gottlieb SS, Deedwania PC, Wikstrand JC. Metoprolol CR/XL in female patients with heart failure: analysis of the experience in metoprolol extended-release randomized intervention trial in heart failure (MERIT-HF). Circulation. 2002;105(13):1585–91.CrossRefGoogle Scholar
  23. 23.
    Shekelle PG, Rich MW, Morton SC, Atkinson CS, Tu W, Maglione M, et al. Efficacy of angiotensin-converting enzyme inhibitors and beta-blockers in the management of left ventricular systolic dysfunction according to race, gender, and diabetic status: a meta-analysis of major clinical trials. J Am Coll Cardiol. 2003;41(9):1529–38.CrossRefGoogle Scholar
  24. 24.
    Hori M, Sasayama S, Kitabatake A, Toyo-Oka T, Handa S, Yokoyama M, et al. Low-dose carvedilol improves left ventricular function and reduces cardiovascular hospitalization in Japanese patients with chronic heart failure: the multicenter carvedilol heart failure dose assessment (MUCHA) trial. Am Heart J. 2004;147(2):324–30.CrossRefGoogle Scholar
  25. 25.
    Bristow MR, Gilbert EM, Abraham WT, Adams KF, Fowler MB, Hershberger RE, et al. Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. MOCHA Investigators Circulation. 1996;94(11):2807–16.CrossRefGoogle Scholar
  26. 26.
    Flather MD, Shibata MC, Coats AJ, Van Veldhuisen DJ, Parkhomenko A, Borbola J, et al. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J. 2005;26(3):215–25.CrossRefGoogle Scholar
  27. 27.
    Yamamoto K, Origasa H, Hori M, Investigators JD. Effects of carvedilol on heart failure with preserved ejection fraction: the Japanese diastolic heart failure study (J-DHF). Eur J Heart Fail. 2013;15(1):110–8.CrossRefGoogle Scholar
  28. 28.
    Fonarow GC. The role of in-hospital initiation of cardioprotective therapies to improve treatment rates and clinical outcomes. Rev Cardiovasc Med. 2002;3(Suppl 3):S2–S10.PubMedGoogle Scholar
  29. 29.
    Swedberg K, Komajda M, Bohm M, Borer JS, Ford I, Dubost-Brama A, et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet. 2010;376(9744):875–85.CrossRefGoogle Scholar
  30. 30.
    McMurray JJ. It is BEAUTIFUL we should be concerned about, not SIGNIFY: is ivabradine less effective in ischaemic compared with non-ischaemic LVSD? Eur Heart J. 2015;36(31):2047–9.CrossRefGoogle Scholar
  31. 31.
    Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Colvin MM, et al. 2016 ACC/AHA/HFSA focused update on new pharmacological therapy for heart failure: an update of the 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines and the Heart Failure Society of America. J Am Coll Cardiol. 2016;68(13):1476–88.CrossRefGoogle Scholar
  32. 32.
    Cohn JN. Blood pressure and cardiac performance. Am J Med. 1973;55(3):351–61.CrossRefGoogle Scholar
  33. 33.
    Franciosa JA, Limas CJ, Guiha NH, Rodriguera E, Cohn JN. Improved left ventricular function during nitroprusside infusion in acute myocardial infarction. Lancet. 1972;1(7752):650–4.CrossRefGoogle Scholar
  34. 34.
    Franciosa JA, Cohn JN. Effects of minoxidil on hemodynamics in patients with congestive heart failure. Circulation. 1981;63(3):652–7.CrossRefGoogle Scholar
  35. 35.
    Miller RR, Awan NA, Maxwell KS, Mason DT. Sustained reduction of cardiac impedance and preload in congestive heart failure with the antihypertensive vasodilator prazosin. N Engl J Med. 1977;297(6):303–7.CrossRefGoogle Scholar
  36. 36.
    Schreiber R, Maier PT, Gunnar RM, Loeb HS. Hemodynamic improvement following a single dose of oral phentolamine. Administration in patients with chronic low output cardiac failure. Chest. 1979;76(5):571–5.CrossRefGoogle Scholar
  37. 37.
    Massie B, Chatterjee K, Werner J, Greenberg B, Hart R, Parmley WW. Hemodynamic advantage of combined administration of hydralazine orally and nitrates nonparenterally in the vasodilator therapy of chronic heart failure. Am J Cardiol. 1977;40(5):794–801.CrossRefGoogle Scholar
  38. 38.
    Pierpont GL, Cohn JN, Franciosa JA. Combined oral hydralazine-nitrate therapy in left ventricular failure. Hemodynamic equivalency to sodium nitroprusside. Chest. 1978;73(1):8–13.CrossRefGoogle Scholar
  39. 39.
    Cohn JN, Archibald DG, Ziesche S, Franciosa JA, Harston WE, Tristani FE, et al. Effect of vasodilator therapy on mortality in chronic congestive heart failure. Results of a veterans administration cooperative study. N Engl J Med. 1986;314(24):1547–52.CrossRefGoogle Scholar
  40. 40.
    Cohn JN, Johnson G, Ziesche S, Cobb F, Francis G, Tristani F, et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med. 1991;325(5):303–10.CrossRefGoogle Scholar
  41. 41.
    Taylor AL, Ziesche S, Yancy C, Carson P, D’Agostino R Jr, Ferdinand K, et al. Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. N Engl J Med. 2004;351(20):2049–57.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Department of Cardiovascular MedicineStanford UniversityStanfordUSA

Personalised recommendations